August 08, 2025

INSL5 Rise Tied to Diarrhoea Severity, Treatment

Circulating Insulin-like peptide 5 concentrations may reflect colonic exposure to bile acids and help stratify treatment response in patients with chronic diarrhoea, including those with irritable bowel syndrome with diarrhoea and bile acid diarrhoea.

Conexiant

July 22, 2025

DNA Methylation Links Mucinous Cystic Neoplasms to Ovarian Tumors

Genome-wide DNA methylation analysis shows that pancreatic and liver mucinous cystic neoplasms share epigenetic profiles with mucinous ovarian tumors

The Pathologist

June 12, 2025

What's the Best Scoring Method in CRC Prognosis?

Study of three systems finds that a simple tumor growth pattern scoring method independently predicts colon cancer–specific survival.

The Pathologist

June 04, 2025

Refining Neuroendocrine Tumor Grading With Ki-67 Imaging

Analysis shows prognostic advantage of whole-slide Ki-67 grading in NET tumors

The Pathologist

June 19, 2025

Bile Acid Dysregulation May Drive Alcoholic Hepatitis Severity

Researchers highlight bile acid disruption in alcohol-associated liver disease and recommend therapeutic targets

The Pathologist

August 07, 2025

Medical Oddities: Cocoa Fights the Flu?

Chocolate fights flu, snails regrow eyes, guts go neural, and past lives go clinical.

Conexiant

August 06, 2025

Bimekizumab Sustains Psoriasis Response for 3 Years

A 3-year analysis of a phase IIIb trial found that bimekizumab, a dual interleukin-17A and interleukin-17F inhibitor, maintained high rates of skin clearance and demonstrated a consistent safety profile in patients with moderate-to-severe plaque psoriasis, including those who switched from secukinumab, an interleukin-17A inhibitor.

Conexiant

August 05, 2025

Periodontal Disease: Systemic Associations Across Multiple Organ Systems

Evidence links periodontal inflammation to systemic dysfunction across cardiovascular, endocrine, renal, respiratory, and neurologic systems.

Conexiant

August 05, 2025

Weight Regain Persists After Anti-Obesity Treatment

A new meta-analysis of 11 randomized controlled trials found that patients began regaining weight as early as 8 weeks after discontinuing anti-obesity medications, with weight gain continuing through 52 weeks.

Conexiant